- Home
- PKE vs RGNX Comparison
PKE vs RGNX Comparison
Compare PKE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- RGNX
- Stock Information
- Founded
- PKE 1954
- RGNX 2008
- Country
- PKE United States
- RGNX United States
- Employees
- PKE N/A
- RGNX N/A
- Industry
- PKE Military/Government/Technical
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PKE Industrials
- RGNX Health Care
- Exchange
- PKE Nasdaq
- RGNX Nasdaq
- Market Cap
- PKE 285.7M
- RGNX 387.0M
- IPO Year
- PKE N/A
- RGNX 2015
- Fundamental
- Price
- PKE $13.44
- RGNX $6.96
- Analyst Decision
- PKE
- RGNX Strong Buy
- Analyst Count
- PKE 0
- RGNX 9
- Target Price
- PKE N/A
- RGNX $32.89
- AVG Volume (30 Days)
- PKE 46.6K
- RGNX 1.0M
- Earning Date
- PKE 01-14-2025
- RGNX 03-13-2025
- Dividend Yield
- PKE 3.71%
- RGNX N/A
- EPS Growth
- PKE N/A
- RGNX N/A
- EPS
- PKE 0.36
- RGNX N/A
- Revenue
- PKE $61,420,000.00
- RGNX $83,328,000.00
- Revenue This Year
- PKE N/A
- RGNX $285.00
- Revenue Next Year
- PKE N/A
- RGNX N/A
- P/E Ratio
- PKE $37.44
- RGNX N/A
- Revenue Growth
- PKE 15.45
- RGNX N/A
- 52 Week Low
- PKE $11.96
- RGNX $5.62
- 52 Week High
- PKE $16.62
- RGNX $21.57
- Technical
- Relative Strength Index (RSI)
- PKE 44.86
- RGNX 54.82
- Support Level
- PKE $13.64
- RGNX $7.96
- Resistance Level
- PKE $14.27
- RGNX $8.35
- Average True Range (ATR)
- PKE 0.34
- RGNX 0.65
- MACD
- PKE 0.06
- RGNX 0.12
- Stochastic Oscillator
- PKE 40.16
- RGNX 63.82
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.